Helicobacter · 2026
Susceptibility-Guided Versus Empirical First-Line Therapy of Helicobacter pylori Infection in Adults: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rocha Manuel Coelho, Gaspar Tiago, Bernardes Carlos, Nunes Pedro Pimentel
Аннотация
BACKGROUND: Antimicrobial resistance undermines empirical first-line regimens for Helicobacter pylori. We compared susceptibility-guided therapy (SGT) versus empirical therapy in adults receiving first-line treatment, focusing on intention-to-treat (ITT) eradication.
MATERIALS AND METHODS: We searched MEDLINE (PubMed), Web of Science, and Scopus from inception to 30 September 2025 for randomized controlled trials (RCTs) and non-randomized comparative studies (NRS) in adults with confirmed H. pylori. Interventions included phenotypic (culture/E-test) or genotypic (PCR) SGT applied to biopsy, stool, or gastric juice specimens; comparators were empirical regimens including bismuth quadruple therapy (BQT) and non-BQT options. The primary outcome was ITT eradication. We pooled risk ratios (RR) with DerSimonian-Laird random-effects, reported I2/τ2, and derived 95% prediction intervals (PI). Subgroups were prespecified by comparator family (BQT vs. other) and specimen/method. Multi-arm studies combined empirical arms within family or split across distinct families.
RESULTS: Forty-two studies met inclusion criteria; all contributed ITT data. RCTs (k = 33) favored SGT over empirical therapy (pooled RR 1.09, 95% CI 1.05-1.13; I2 73%; 95% PI 0.92-1.30). NRS (k = 12) were directionally consistent (pooled RR 1.15, 95% CI 1.10-1.22; I2 75%; 95% PI 0.99-1.35). In RCTs, effects were neutral-to-modest vs. BQT (RR 1.03, 95% CI 0.97-1.10) and clearer vs. other empirical regimens (RR 1.12, 95% CI 1.06-1.18).
CONCLUSIONS: In adult first-line therapy, SGT achieves at least non-inferior-and often superior-eradication versus empirical regimens; the incremental benefit is attenuated where BQT is standard. These findings support selective, and increasingly justified, integration of susceptibility testing in settings with clinically relevant resistance.
MATERIALS AND METHODS: We searched MEDLINE (PubMed), Web of Science, and Scopus from inception to 30 September 2025 for randomized controlled trials (RCTs) and non-randomized comparative studies (NRS) in adults with confirmed H. pylori. Interventions included phenotypic (culture/E-test) or genotypic (PCR) SGT applied to biopsy, stool, or gastric juice specimens; comparators were empirical regimens including bismuth quadruple therapy (BQT) and non-BQT options. The primary outcome was ITT eradication. We pooled risk ratios (RR) with DerSimonian-Laird random-effects, reported I2/τ2, and derived 95% prediction intervals (PI). Subgroups were prespecified by comparator family (BQT vs. other) and specimen/method. Multi-arm studies combined empirical arms within family or split across distinct families.
RESULTS: Forty-two studies met inclusion criteria; all contributed ITT data. RCTs (k = 33) favored SGT over empirical therapy (pooled RR 1.09, 95% CI 1.05-1.13; I2 73%; 95% PI 0.92-1.30). NRS (k = 12) were directionally consistent (pooled RR 1.15, 95% CI 1.10-1.22; I2 75%; 95% PI 0.99-1.35). In RCTs, effects were neutral-to-modest vs. BQT (RR 1.03, 95% CI 0.97-1.10) and clearer vs. other empirical regimens (RR 1.12, 95% CI 1.06-1.18).
CONCLUSIONS: In adult first-line therapy, SGT achieves at least non-inferior-and often superior-eradication versus empirical regimens; the incremental benefit is attenuated where BQT is standard. These findings support selective, and increasingly justified, integration of susceptibility testing in settings with clinically relevant resistance.